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CompARE is a pragmatic multicentre open-label phase III
randomised controlled trial aiming to determine if intensi-
fication of treatment in intermediate and high risk oro-
pharyngeal cancer (OPC) patients improves the definitive
primary outcome measure of overall survival time. The
trial evaluates three experimental arms separately against
one control arm using a MAMS design, with three interim
assessments of disease-free survival time. Experimental
arms will be discontinued if they fail to meet the interim
assessment criteria. The timing of these assessments is
driven by the number of control events, with the study
engineered so these occur approximately annually. The
design characteristics will be presented.
A potential additional experimental arm for treatment of
OPC was proposed during CompARE initiation, and could
be introduced into the trial after one year if approved. The
straightforward implication is an increase in the number
of patients required to recruit per year or an increase in
trial duration. However in a complex MAMS design, a bal-
ance of multiple factors such as a feasible sample size, trial
duration and appropriate number and timing of interim
assessments with appropriate statistical error rates, have to
be carefully considered.
Using the nstage and artpep programs in Stata, a review
of the operating characteristics of both the original design
and expanded design with the new experimental arm was
undertaken. The recruitment and statistical implications
of the addition of the new experimental arm and an eva-
luation of the study duration to changes in recruitment
predictions will be presented.
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